FOCUS
While cardiac pacemaker devices capable of sensing and responding to patient physiology have been in clinical use for over 50 years, 41 similar efforts to develop a "closedloop" DBS device have been delayed; this is likely due to the complexity of brain signals and uncertainty surrounding the clinical significance of recordable brain activity. These roadblocks are increasingly surmountable, with advances in technology, development of applicable algorithms, and a greater understanding of neurophysiology.
Closed-loop DBS represents a subset of bidirectional brain computer interfaces; a comprehensive review of such systems is beyond the scope of this paper, which will focus on relatively well-established approaches to the treatment of movement disorders. The goal is to provide an overview of the features of a closed-loop system, with attention paid to signal sources and biomarkers, general approaches to feedback control, and clinical data when available.
Methods
A literature search using the keywords "closed-loop DBS" and "adaptive DBS" was performed using the PubMed database. The search was conducted for all articles published up until March 2018.
The keywords "closed-loop DBS" resulted in 156 articles, while "adaptive DBS" returned 100 articles. The procedure for narrowing these results for in-depth review is presented in Fig. 1 .
General Description of a "Closed-Loop" Approach
A general control system diagram for a putative closedloop DBS system is presented in Fig. 2 . First, the signal is extracted from sensor data and used to predict the patient's current state. This signal can include data derived from an external sensor (e.g., electroencephalography [EEG] or inertial measurement unit [IMU] ), or implanted sensor (e.g., electrocorticography [ECoG] , local field potentials [LFPs] , or action potentials [APs] ). The system must identify useful features, including, for example, the desynchronization of neural oscillations. Algorithms employing models of neurochemical or electrophysiological dynamics allow generation of an estimated clinical state, which in turn drives selection and optimization of stimulation parameters in order to achieve desired features in the reference signal. The controller examines the reference signal and the desired features, calculates error, and outputs a control signal that is passed to the actuator, which applies the predicted beneficial stimulation parameters. This ultimately influences the signals detected by the sensor, serving as a surrogate for the benefit of DBS, bringing the detected reference signal and desired features closer together (Fig. 2) .
Results

Approaches to Biomarkers: Available Signals and Features
Various biological signals, including kinematic data (accelerometer) and those obtained using electromyography (EMG), EEG, ECoG, LFPs, and APs, have been considered as biomarkers for closed-loop DBS (Table 1) . Each varies with respect to invasiveness, resolution, signal content, and clinical relevance. For example, EEG electrodes are noninvasive but measure voltage changes from a large
FIG. 1.
A flow diagram illustrating the types of papers included and excluded for reviewing in this article. The search terms "closedloop DBS" and "adaptive DBS" returned 156 and 100 articles, respectively. Duplicate articles, non-English language articles, and articles clearly not related to DBS were excluded. Primary data analyses were divided into human and nonhuman studies, resulting in 71 articles. Those related to treatment of movement disorders (50 total) were included for in-depth review.
volume, with little usable signal at high frequencies. 6 A microelectrode capable of measuring APs will have a small contact area, allowing for very high spatial and frequency resolution. 38 On the other hand, AP recordings from small groups of neurons can change from day to day, which may limit their application for long-term stimulation. 45 Signals such as accelerometer data are noninvasive, but such kinesthetically rich information can be noisy and 
FIG. 2.
General diagram for conceptualizing the closed-loop DBS system. Data gathered by a sensor is converted into a measured feature. This reference signal is passed to a state estimator, which generates a desired feature and desired DBS parameters. The controller compares the reference signal and desired signal, generates an error signal, and compensates to generate a control signal. This is passed on to the actuator, which influences stimulation at the basal ganglia. The effects on brain and behavior are detected by the sensor, which provides closed-loop feedback into the system.
requires telemetry between an external device and an implanted neurostimulator, driving up energy costs.
Feature Extraction and Classification
Feature extraction transforms time-series data for subsequent processing and potentially improves data processing efficiency. Signals can be examined in the time, frequency, or time-frequency domain. For example, the oscillatory activity of neuronal ensembles can be characterized by techniques to estimate spectral power in the frequency domain, such as short-time Fourier transform or wavelet transformations, and changes within particular frequency bands have been correlated to behavior in well-defined regions of the cortex and subcortical structures. We will discuss a subset of these techniques in the context of particular studies. Likewise, there are many approaches to the identification and segregation of patterns used to generate state estimations for closed-loop control. Suffice it to say that some of these algorithms, such as linear discriminant analysis, may be embedded within DBS devices, such as the Activa PC+S, to classify signals and adapt to dynamic patient requirements.
Kinematic Data
Data from accelerometers or IMUs can be used to detect symptoms such as tremor. A feedback loop based on the presence or absence of tremor or the onset of movement, can be used to control an adaptive DBS device. One example of both approaches can be seen in a case report by Herron et al., 22 which illustrates several advantages and disadvantages of this approach.
IMU data were collected using a smartwatch worn on the affected limb. These data were processed and fed into a control algorithm adjusting stimulation according to the magnitude of the tremor band power (4-8 Hz) on the 3 gyroscope channels. This tremor-modulated approach reduced the average tremor band amplitude by about 59% when compared to open-loop DBS, but it used only 16% of baseline stimulation, representing a 6.5% gain in efficiency for every 1% increase in tremor (Fig. 3) . 22 A similar, tremor-modulated approach has been used in PD patients. 35 Stimulation amplitude was modulated as a proportion of detected tremor using an IMU, resulting in a 37% reduction in average tremor amplitude with an energy savings of more than 75%. An important difference in considering these results is the stochastic, unpredictable nature of resting tremor in PD patients versus the predictable, movement-associated tremor in ET.
In an alternative approach, Cagnan et al. extracted the dominant phase of tremor in ET patients. Low-frequency (approximately 4 Hz), phase-locked stimulation was provided at randomized phases relative to the tremor phase, and the most effective phase-offset was determined empirically. Phase-locked DBS was then delivered during tremor-provoking posture holding. This approach achieved up to 87% symptom suppression. 11 Power savings in this system are achieved using a lower stimulation frequency. Another potential benefit of this phase-locked approach is mitigation of stimulation-related side effects; in principle, functional networks characterized by oscillatory networks are not affected by stimulation if they are not entrained to the same phase as the patient's tremor.
Data from kinematic sensors, such as accelerometers, have revealed quantitatively significant differences between patients with PD in "on" and "off" medication states, and also between PD patients and healthy individuals. 8 Preliminary data on the use of smartphones to gather similar kinematic data show that symptom severity can be predicted for modalities, such as gait, 16 bradykinesia, 29 and dyskinesias. 53 Data of this type could potentially be used to provide a viable reference signal for adaptive DBS systems, using individual patient models of the disease state to modulate delivery of DBS.
Electromyography
Surface EMG (sEMG) from symptomatic extremities can provide useful information as a biomarker in closedloop DBS. 54 Graupe et al. performed a trial in which a patient undergoing DBS for ET underwent test stimulation with simultaneous sEMG monitoring. The signals from sEMG were filtered by 4 frequency bands (1-2, 2-4, 4-8, and 8-16 Hz) and analyzed by discrete wavelet transforms, which revealed that the activated power of bandpass sEMG signals (4-8 Hz) could be used to predict the onset of tremor before tremor appeared. 19 Several case series have implemented the use of sEMG as a sensor for closed-loop DBS. 22, 62 Yamamoto et al. used power in a 3-Hz tremor band to trigger stimulation. 62 Another study examining ET and PD patients employed wavelet entropy for measuring the similarity and difference between different segments of the signal. The power band in the 8-to 16-Hz range showed high predictive value for detecting tremor, achieving 100% sensitivity and 85.7% accuracy for ET and 80.2% accuracy for PD trials. 5 These symptom-modulated approaches rely on the presence of tremor to initiate stimulation.
Another approach is to initiate stimulation in a movement-modulated fashion, providing DBS throughout any detected movement. Using surface EMG, Herron et al. 22 showed that this approach provided 92% of the tremor control generated by open-loop DBS with 53% of the power usage, resulting in a 2:1 gain in efficiency. This approach was compared with a tremor-modulated, IMU-based, closedloop model, detailed in the previous section. Both methods were 100% accurate in detecting either movement or rest conditions, on a per-epoch basis, showing that kinematic control for closed-loop DBS can be very accurate. These data illustrate an interesting trade-off inherent in approaches that detect the presence or absence of a symptom: in order for the IMU-based, tremor-modulated system to provide stimulation, some tremor must be present, entailing poorer tremor control. Movement-modulated stimulation, on the other hand, provided better tremor control at the cost of a higher rate of power consumption. However, noise in the EMG signal can be caused by small movements of the electrodes, making it potentially difficult to extract a reliable signal during real-world use.
3 Moreover, reliable sEMG markers for cardinal symptoms of PD, such as rigidity and bradykinesia, have not yet been developed.
Electrocorticography
Electrocorticography has been widely studied in patients with epilepsy 4, 55 and is currently used as a biomarker in a brain-responsive neurostimulator (RNS system, Neuropace). 18 While widely considered a disease affecting the basal ganglia, there is evidence that information regarding the disease state can be extracted from cortical signals using ECoG.
PD patients show larger beta desynchronization in early motor preparation and higher gamma power during rest and movement when compared with ET patients. 52 Other studies have shown excess in PD patients; beta-band phase (13-30 Hz) modulation of gamma-band amplitude (50-200 Hz) was observed in the primary motor cortex (M1) of patients at rest, but this coupling is significantly stronger in PD patients. 13, 27 Interestingly, phase-amplitude coupling within M1 decreased in PD patients during effective DBS, both at rest and during movement. These studies provide evidence that cortical signals are a potential biomarker for successful treatment of symptoms with DBS.
Recent studies using the Activa PC+S system offer the ability to perform long-term, multisite recording in DBS patients. In one study, the electrodes for DBS were implanted at the subthalamic nucleus (STN), with ipsilateral cortical electrodes overlying the sensorimotor cortex. The presence of dyskinesias was highly correlated with narrowband gamma oscillations in the motor cortex between 60 and 90 Hz, independent of voluntary movements. 56 During therapeutic DBS, when dyskinesias are present, the narrowband gamma oscillations shift in frequency to one-half the stimulation frequency. This finding suggests a viable cortical biomarker for closed-loop DBS with respect to the treatment of dyskinesias.
An alternative to using ECoG-derived LFPs as markers for disease state is their use to detect behavior associated with the need for DBS. In an ET study using the Medtronic PC+S system, a cortical strip was placed over the hand sensorimotor cortex in addition to the DBS electrode in the thalamus of the ventral intermediate nucleus (VIM). Movement-related beta-band desynchronization in the cortical signal was used to drive stimulation at the VIM; this system provides closed-loop stimulation based on the premise that therapy for ET is required only during intentional movement. Evaluation of the accuracy of the controller showed that stimulation was on for 100% of prompted movement tasks and was on throughout tasks such as spiral drawing or water pouring. 23 This demand-driven paradigm for ET did reveal challenges of an "on-off" approach to closed-loop DBS: individual sensitivity to the rate of amplitude changes must be taken into consideration. Use of a bipolar electrode configuration mitigates paresthesias during initiation of stimulation. More complex controller algorithms are also being developed to alleviate the need to turn a system from a fully "off" to a therapeutic stimulation level. In general, limiting the slew rate can avoid paresthesias, and, while this results in some tremor at movement initiation, it is quickly suppressed. Interestingly, this initial presence of tremor may be difficult to detect for both the patient and expert clinicians; the difference in tremor control between using constant DBS and closed-loop DBS employing this demand-driven strategy was indistinguishable to blinded clinical raters (manuscript in submission).
Subcortical Local Field Potential
Local field potentials reflect neural processes occurring in the extracellular space around a recording electrode. This finding has been corroborated in patients implanted with the Activa PC+S system, where peaks in the 13-to 35-Hz range were reliably seen, suppressed by levodopa, and correlated with parkinsonian motor impairment on the individual level across time points and dopaminergic states. 43 The suitability of using beta-band power thresholds to trigger STN stimulation has been demonstrated in humans in the acute setting. 32, 33 In a series of studies, LFPs were recorded from the STN, bandpass-filtered between 3 and 37 Hz, and converted to beta amplitude by rectifying and smoothing. Monopolar stimulation was triggered when beta power crossed a user-defined threshold and terminated while beta power dropped below threshold. The results were superior to those of traditional open-loop stimulation on blinded assessment. For unilateral therapy, a 50% reduction in UPDRS-III scores was seen during closed-loop stimulation compared with 30% improvement during open-loop stimulation, with a reduction in stimulation time of 44%. 33 Importantly, similar results were not seen with random, intermittent stimulation, suggesting that intermittency alone was not responsible for the additional benefit. Similar results were noted during bilateral therapy. 32 These studies employed a straightforward control algorithm, with voltage adjustments designed to elicit clinical benefit without paresthesias, at a threshold for stimulation heuristically determined to provide about 50% time-on-stimulation. Interestingly, even with this simple algorithm, the effect of levodopa administration was detectable as significantly decreased time-on-stimulation based on beta-band power, without a deterioration in motor state, showing that the beta-band signal used for closed-loop control accurately reflected the clinical need for stimulation in the face of medication administration. 32 Notably, follow-up studies have shown that a significant improvement in speech intelligibility was seen during closed-loop DBS when compared with conventional therapy. 34 These impressive results have been described in patients with externalized DBS leads, with the attendant confounds of DBS in the acute setting. Longer-term studies are in progress, and the ability of closed-loop DBS to provide similar or superior motor benefit, an improved side-effect profile, with a time-on-stimulation on the order of 45% when compared to constant stimulation, is an exciting prospect.
Neurochemical Dynamics
Dopamine has an important role in motor and cognitive function and has long been implicated in the pathophysiology of PD. 14, 39, 58 It stands to reason that dopamine dynamics may be a potential biomarker for a closed-loop system. The development of fast-scan cyclic voltammetry at carbon microelectrodes provides a method for real-time in vivo measurement of neurochemical changes in dynamic brain processes; refinement of these systems has made it possible to measure response to pharmacological, cognitive, behavioral, and neuromodulatory interventions, such as DBS. 31 In humans, this methodology has been applied to detect rapid (subsecond) measurements of dopamine release in a PD patient during decision-making tasks. 26 The relationship between the dynamics of dopamine release and DBS at the STN has not been elucidated in humans; however, detectable dopamine increases at "therapeutic" charge densities applied during DBS have been observed in the porcine STN. 30 Such a real-time monitor of dopamine levels provides a potential method for closed-loop control of a DBS system. Similar methodology has been applied in patients undergoing DBS for ET. In 8 patients, localized release of adenosine was noted during placement of a DBS electrode at the VIM, with some patients showing a voltagedependent response to DBS at the same site. 12 This study, however, did not correlate adenosine release with tremor reduction.
Approaches to Feedback and DBS Parameter Modulation
Open-loop DBS requires neurologists to adjust stimulation parameters and evaluate results in an outpatient clinical setting. Selectivity and efficiency are important in determining optimal stimulation parameters; the goal is to use the minimum amount of stimulation to achieve clinical effect by activating the targeted neural elements without nontarget effects.
Current clinical DBS systems deliver a constant train of pulses, with adjustments possible in spatial application across electrode configurations and variation of amplitude, pulse-width, and frequency of the stimulation train. In principle, any of these parameters may be modified using a closed-loop approach (Table 2) .
Amplitude Response
Potentially, the most straightforward approach involves an amplitude response: stimulation parameters are determined using traditional programming, and closed-loop control merely modulates stimulation amplitude in response to an estimated clinical state. Most of the more mature approaches to closed-loop DBS take this approach, employing either an event-dependent, on/off control, or continuous-time control where stimulation amplitude varies proportionately to the amplitude of the signal. As described above, efficacy of this approach to feedback has been employed with kinematic markers in PD 35 and ET, 22 electrocorticography in ET, 23 and STN LFPs in PD.
32,33
Model-Based Approaches The cardinal symptoms of PD can be conceived of as the consequence of pathological synchronization of neural oscillations in a widespread brain network. Intraoperative recordings demonstrate that while pathologic beta-band oscillations in STN LFPs may be generated locally, 59 this excessive synchronization can be detected outside the basal ganglia. 9 Karamintziou et al. illustrated a data-driven computational model by using neuronal synchronization dynamics within and outside the STN. Stimulation patterns were designed with various stimulation frequencies (80 Hz and 130 Hz) and temporal regularity. Low-frequency, irregular patterns of stimulation and low-frequency periodic stimulation interrupted by bursts of pulses exerted the strongest desynchronizing effect on neuronal activity. Thus, detecting and disrupting this network of oscillatory neurons is potentially another strategy for feedback control. 25 Popovych et al. presented a delayed feedback stimulation method, which combined high-frequency DBS stimulation and pulsatile delayed feedback to desynchronize abnormal neuronal activity. 46, 47 Such methods include pulsatile linear delayed feedback (LDF) or pulsatile nonlinear delayed feedback as methods to use to counteract abnormal neuronal synchronization present in PD. Further studies have employed pulsatile multisite LDF by using signal not only from the STN but also external globus pallidus neurons. However, the efficacy of the pulsatile multisite LDF in inducing desynchronization was much lower than that of the pulsatile LDF. 48 The concept of vanishing-stimulation control 57 introduces a model wherein stimulation is coupled and proportional to the pathologic synchronous rhythm. LFPs are recorded from 1 electrode and fed back into the system by an application electrode; the feedback loop contains a passive oscillator that applies a phase shift in stimulation varying according to system dynamics (e.g., latency). The passive oscillator is driven by pathologic oscillations; the phaseshifted stimulation suppresses the pathologic rhythm and vanishes as suppression is achieved. This approach has not been implemented in any clinical studies.
A related approach described previously has been used to treat ET, predicated on the observation that DBS at tremor frequency can entrain neural oscillations and modulate peripherally detected tremor amplitudes. 10 This approach decouples the tremor network and was able to provide significant tremor relief with significant energy savings when compared to conventional high-frequency stimulation.
11 In contrast to amplitude-responsive approaches, such modelbased approaches to feedback can, in principle, spare other neural activities that are not phase-locked to stimulation frequencies.
Other Approaches
Modulation of stimulation parameters other than amplitude via closed-loop control has not been well characterized. One potentially interesting parameter to modulate may be frequency of stimulation.
There are some data that low-frequency (60 Hz) stimulation may prove less likely to alter verbal fluency and gait when compared to higher-frequency (130 Hz) stimulation. 17, 40, 60, 61 The literature reveals variation in patient response, 40 potentially transient effectiveness, 51 and often decreased effectiveness in treating appendicular symptoms, tempering enthusiasm for application of low-frequency 44 STN LFP features, such as synchronization and interhemispheric connectivity features based on wavelet transform and Granger causality approaches, have achieved an average accuracy of 99.8% for movement identification, and 81.5% for laterality classification. 36 In chronic recordings in DBS patients with akinetic rigid PD, a trend toward decreased beta power when walking was exhibited. 50 The ability to use LFP features in STN to distinguish between behavioral states, if coupled to modulation of stimulation parameters such as frequency, which may be associated with a differential effect on axial versus appendicular symptoms, may provide another method for feedback control of a closed-loop DBS system that is responsive to patient needs.
Discussion
Closed-loop DBS seeks to improve an already effective therapy by coupling patient physiology to therapy delivered. To do so, an estimation of the patient's physiological state is needed, as well as control algorithms to modify and deliver therapy and assess the effects of that therapy. Differing clinical patterns may be characterized by different neural biomarkers, 28, 37, 49 and it may be the case that patient-specific models incorporating multiple markers may be needed for the most effective clinical outcomes.
The long-term efficacy and efficiency of even the most mature attempts at closed-loop control is not established. In general, closed-loop DBS has been shown to use less power than an open system. 34 However, most mature systems have thus far outsourced processing to an external computer system. 11, 23, 32, 34, 35 For less-mature technologies, such as the wireless fast-scan cyclic voltammetry systems, the added power costs are completely unknown. Development of more efficient and patient-friendly rechargeable systems is likely to mitigate this concern.
Importantly, even the most mature closed-loop approaches rely on the open-loop model to determine stimulation parameters. As new DBS systems with currentsteering capabilities become increasingly popular, the search space that must be explored to determine "optimal" parameters, even in a static setting, will increase dramatically. Development of algorithms to allow automated DBS programming will be needed to fully realize the benefits of this technology.
Ultimately, the appeal of closed-loop DBS lies in the potential to treat symptoms in response to patient physiology. This may be implemented in a variety of ways, and will be facilitated by technological advances in sensor technology, in the machine-learning algorithms used to extract relevant signal features and to identify and respond to changes in estimated patient state, in the hardware used to deliver that stimulation, and by our increasing understanding of the cortical and subcortical dynamics underlying the pathologies treated.
Conclusions
DBS is a successful therapy for movement disorders such as Parkinson's disease, essential tremor, and dystonia. Traditional DBS therapy is open loop; parameters are determined and adjusted in a clinical setting and do not, for the most part, take into account variations in patient symptoms and need for stimulation. Closed-loop DBS seeks to employ biomarkers, derived from sensors such as EMG, ECoG, and LFP, to optimize stimulation parameters for clinical treatment. Preliminary data suggest that patientresponsive stimulation may provide superior symptom relief compared with open-loop DBS, may mitigate some of the side effects of DBS, and may be more power efficient than constant stimulation. However, patient-responsive therapy for movement disorders is yet in the early stages of development, requiring additional studies to determine what approaches are feasible, efficacious, and efficient.
